JP2006510654A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510654A5
JP2006510654A5 JP2004558236A JP2004558236A JP2006510654A5 JP 2006510654 A5 JP2006510654 A5 JP 2006510654A5 JP 2004558236 A JP2004558236 A JP 2004558236A JP 2004558236 A JP2004558236 A JP 2004558236A JP 2006510654 A5 JP2006510654 A5 JP 2006510654A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
formulation according
kinase inhibitor
patient
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004558236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/040140 external-priority patent/WO2004053107A2/en
Publication of JP2006510654A publication Critical patent/JP2006510654A/ja
Publication of JP2006510654A5 publication Critical patent/JP2006510654A5/ja
Pending legal-status Critical Current

Links

JP2004558236A 2002-12-06 2003-12-05 糖尿病を処置する方法 Pending JP2006510654A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43124102P 2002-12-06 2002-12-06
PCT/US2003/040140 WO2004053107A2 (en) 2002-12-06 2003-12-05 Methods for treating diabetes

Publications (2)

Publication Number Publication Date
JP2006510654A JP2006510654A (ja) 2006-03-30
JP2006510654A5 true JP2006510654A5 (enExample) 2007-02-01

Family

ID=32507688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004558236A Pending JP2006510654A (ja) 2002-12-06 2003-12-05 糖尿病を処置する方法

Country Status (6)

Country Link
US (1) US20040171659A1 (enExample)
EP (1) EP1583535A4 (enExample)
JP (1) JP2006510654A (enExample)
AU (1) AU2003299652A1 (enExample)
CA (1) CA2511763A1 (enExample)
WO (1) WO2004053107A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7765004B2 (en) * 2005-04-28 2010-07-27 Cardiac Pacemakers, Inc. Methods and systems for managing fusion and noise in cardiac pacing response classification
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
CA2857374A1 (en) * 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Camkii, ip3r, calcineurin, p38 and mk2/3 inhibitors to treat metabolic disturbances of obesity
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4619652A (en) * 1982-12-23 1986-10-28 Alza Corporation Dosage form for use in a body mounted pump
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP2000506532A (ja) * 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
PL340412A1 (en) * 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6599710B1 (en) * 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
AU772295B2 (en) * 1999-05-21 2004-04-22 Scios Inc. Indole-type derivatives as inhibitors of p38 kinase

Similar Documents

Publication Publication Date Title
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
JP2003520232A5 (enExample)
JP2010530431A5 (enExample)
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ITMI20031617A1 (it) Microcapsule a doppio strato di polisaccaridi utilizzabili
JP2010502564A (ja) 眼科用経皮吸収型製剤
WO2005018605A3 (en) Novel formulation of ropinirole
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
JP2005526024A5 (enExample)
JP2009541387A5 (enExample)
KR101432246B1 (ko) 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물
PT1401413E (pt) Uso de inibidores da tirosina cinase para tratar doenças alérgicas
JP2006510654A5 (enExample)
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
CA2608163A1 (en) Hydralazine compositions and methods
JP2008538362A (ja) タンパク質の成熟の遮断を介して疾患を処置するための方法、タンパク質ジスルフィドイソメラーゼなどの分子シャペロンの機能を阻害する、またはグリコシル化を妨害する化合物、それらを含む薬学的組成物、および治療剤を同定するためのスクリーニング方法
JP2007504268A5 (enExample)
SE0002729D0 (sv) Novel compound form
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
NO20060651L (no) Fremgangsmate for behandling av virale infeksjoner
CA2504873A1 (en) Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one
KR20170124322A (ko) 알러지 질환 치료제 전달을 위한 용해성 미세바늘 패치
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания